Tirzepatide TR30 is a high-purity synthetic modified peptide research compound that is used for metabolic mechanisms, receptor interactions, and peptide pharmacology studies via the GLP-1 and GIP dual receptor signaling pathways.
Tirzepatide TR30 is a synthetic esterified peptide compound consisting of 39 amino acids, belonging to the GLP-1/GIP dual receptor agonist class. This molecule was designed using structural optimization and fatty acid modification to investigate incretin-related signaling pathways, receptor activation mechanisms, cellular metabolic regulation, and the structure-function relationships of multi-target peptides. TR30 is supplied as a white to off-white lyophilized powder and its quality was verified by analytical methods including HPLC purity detection and LC-MS identification.
Tirzepatide TR30 is primarily used in metabolic biology, molecular pharmacology, and peptide engineering research, including studies on the GLP-1R/GIPR dual receptor signaling pathway, receptor binding mechanism analysis, cell signal transduction, glucose metabolism, energy balance regulation, lipid metabolism, and the development of novel metabolic regulatory peptides. This compound can be used to explore the synergistic effects of dual receptors and the regulatory mechanisms in complex metabolic networks.
Freeze-dried powder state:
Recommended:
Long-term storage:
-20℃
Requirements:
✅ Protect from light
✅ Dry
✅ Store in an airtight container
Avoid:
High temperatures
Repeated freeze-thaw cycles
Prolonged exposure to air
Retatrutide (RT10) is a synthetic peptide research compound designed as a triple...
Retatrutide (RT20) is a novel synthetic modified peptide, with the research code...
Retatrutide RT30 is a 30mg research-grade peptide product of Retatrutide (LY3437...
Contact our team for volume discounts and custom peptide services
Weitai Bio is a national high-tech enterprise specializing in the research, development, production, and sales of peptide drugs. It is also a leading global supplier of high-quality peptides, consistently focusing on peptide drugs and small nucleic acid fields.